BACKGROUND: Anti-Xa activity (AXA) in patients with nonvalvular atrial fibrillation (NVAF) and relationship to bleeding events remains unclear. METHODS: We evaluated AXA in 94 patients at both trough and peak rivaroxaban concentrations. Rivaroxaban dosage was determined according to creatinine clearance (CrCl): 10 and 15mg once daily for patients with CrCl 15-49 and CrCl ≥50mL/min, respectively. AXA value distribution and its association with bleeding events were examined in enrolled subjects. RESULTS: The mean peak AXA level was significantly higher than the mean trough level (1.98±0.81 vs. 0.16±0.15IU/mL; p<0.001). The peak AXA level significantly differed among patients with CrCl 15-29, 30-49, 50-79, and ≥80mL/min (2.51±0.83, 1.72±0.76, 2.05±0.82, and 1.66±0.51IU/mL, respectively; p=0.004). Major and non-major clinically relevant bleeding events occurred in 22 patients (23.4% and 14.6% per year, respectively). The mean peak AXA level was significantly higher in patients who experienced bleeding events than in those who did not (2.40±0.70 vs. 1.84±0.80IU/mL; p=0.001). A Cox multivariate analysis showed that the peak AXA level was independently related to the incidence of major and non-major clinically relevant bleeding events (p=0.012). Cumulative bleeding rates were significantly higher in patients with high peak AXA levels (p<0.001). CONCLUSION: Peak AXA level was an independent predictor for bleeding events in Japanese NVAF patients receiving rivaroxaban.
BACKGROUND: Anti-Xa activity (AXA) in patients with nonvalvular atrial fibrillation (NVAF) and relationship to bleeding events remains unclear. METHODS: We evaluated AXA in 94 patients at both trough and peak rivaroxaban concentrations. Rivaroxaban dosage was determined according to creatinine clearance (CrCl): 10 and 15mg once daily for patients with CrCl 15-49 and CrCl ≥50mL/min, respectively. AXA value distribution and its association with bleeding events were examined in enrolled subjects. RESULTS: The mean peak AXA level was significantly higher than the mean trough level (1.98±0.81 vs. 0.16±0.15IU/mL; p<0.001). The peak AXA level significantly differed among patients with CrCl 15-29, 30-49, 50-79, and ≥80mL/min (2.51±0.83, 1.72±0.76, 2.05±0.82, and 1.66±0.51IU/mL, respectively; p=0.004). Major and non-major clinically relevant bleeding events occurred in 22 patients (23.4% and 14.6% per year, respectively). The mean peak AXA level was significantly higher in patients who experienced bleeding events than in those who did not (2.40±0.70 vs. 1.84±0.80IU/mL; p=0.001). A Cox multivariate analysis showed that the peak AXA level was independently related to the incidence of major and non-major clinically relevant bleeding events (p=0.012). Cumulative bleeding rates were significantly higher in patients with high peak AXA levels (p<0.001). CONCLUSION: Peak AXA level was an independent predictor for bleeding events in Japanese NVAF patients receiving rivaroxaban.
Authors: Andrea Huppertz; Lars Werntz; Andreas D Meid; Kathrin I Foerster; Jürgen Burhenne; David Czock; Gerd Mikus; Walter E Haefeli Journal: Br J Clin Pharmacol Date: 2018-10-11 Impact factor: 4.335
Authors: Antonia Brings; Marie-Louise Lehmann; Kathrin I Foerster; Jürgen Burhenne; Johanna Weiss; Walter E Haefeli; David Czock Journal: Br J Clin Pharmacol Date: 2019-05-09 Impact factor: 4.335
Authors: Andrea Huppertz; Caspar Grond-Ginsbach; Chris Dumschat; Kathrin I Foerster; Jürgen Burhenne; Johanna Weiss; David Czock; Jan C Purrucker; Timolaos Rizos; Walter E Haefeli Journal: BMC Pharmacol Toxicol Date: 2019-08-29 Impact factor: 2.483
Authors: Nicholas Jakowenko; Steffany Nguyen; Melanie Ruegger; Ashley Dinh; Eric Salazar; Kevin R Donahue Journal: Thromb Res Date: 2020-09-06 Impact factor: 3.944
Authors: Timolaos Rizos; Andreas D Meid; Andrea Huppertz; Chris Dumschat; Jan Purrucker; Kathrin I Foerster; Jürgen Burhenne; David Czock; Ekkehart Jenetzky; Peter A Ringleb; Walter E Haefeli Journal: J Stroke Date: 2022-01-31 Impact factor: 6.967